Central Nervous System Disorders Therapeutics Market Analysis & Forecast: 2026-2033
The global central nervous system disorders therapeutics market is estimated to be valued at USD 139,307 Mn in 2026 and is projected to grow at a CAGR of 7.4% during the forecast period (2026-2033), reaching USD 228,639 Mn by 2033. This growth is attributable to rising prevalence of neurological and psychiatric disorders, growing awareness and diagnosis of CNS conditions, and introduction of innovative therapies like biologics and gene-based treatments. Over 3 billion people, around 43% of the global population live with a neurological condition. Neurological disorders are the leading cause of disability and health loss worldwide, accounting for more than 11 Mn deaths each year.
The global central nervous system disorders therapeutics market is projected to register steady growth during the forecast period. This is primarily due to rising incidence of neurological and psychiatric disorders, increasing geriatric population, growing awareness of early diagnosis and treatment, and continuous advancements in drug development.
Increasing investments in neuroscience research and development of targeted biologics, gene therapies, and personalized treatment approaches are also expected to support market expansion over the coming years. Similarly, rising popularity of personalized and precision medicine will bode well for the target market during the forecast period.
Genetic profiling, biomarkers, and patient-specific treatment approaches are increasingly being used to improve treatment outcomes in CNS disorders. Moreover, combination drug regimens are becoming more common to improve efficacy in complex conditions like schizophrenia and depression.
Central nervous system (CNS) disorders comprise neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, migraines, meningitis, encephalitis, and spinal cord injuries. Rising prevalence of these conditions is expected to fuel demand for effective therapeutic interventions as well as boost central nervous system (CNS) disorders therapeutics market growth during the forthcoming period.
Shift towards disease-modifying therapies is an emerging trend in the central nervous system disorders therapeutics market. There is a rising trend toward therapies that slow or modify disease progression rather than only managing symptoms, especially in Alzheimer’s and Parkinson’s disease. For instance, UCB recently (2026) announced acquisition of Neurona Therapeutics to strengthen UCB’s epilepsy portfolio and support the development of next-generation disease-modifying therapies.
According to Coherent Market Insights' latest central nervous system disorders therapeutics market analysis, neurodegenerative disorders are slated to lead the market, capturing a 32% share in 2026. This dominance is attributable to rising prevalence of neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
For instance, according to recent research, the number of people living with Parkinson’s disease is estimated to reach approximately 25.2 million by 2050. This anticipated increase in burden of neurological diseases is expected to create high demand for central nervous system disorders therapeutics during the forecast period.
These chronic, progressive disorders require long-term pharmacological management, resulting in rising demand for therapeutic products. In addition, the growing global aging population and ongoing advancements in disease-modifying therapies are expected to also boost segment growth in the coming years.
To learn more about this report, Request Free Sample
By drug class, antidepressants are anticipated to dominate the market, accounting for a revenue share of 25% in 2026. This is mostly due to rising prevalence of depression, anxiety, and other mood disorders across the world, increasing awareness of mental health, and improving access to treatment. Globally, an estimated 5.7% of adults live with depression.
According to the Similarly, anxiety disorders are becoming common. This rising burden, in turn, is expected to fuel demand for antidepressants like SSRIs, SNRIs, atypical antidepressants, and generic formulations during the forecast period.
Rising adoption of newer antidepressants with enhanced safety profiles and fewer side effects, along with expanding healthcare coverage and favorable reimbursement policies in developed countries, is also driving market demand. In addition, continuous research and development efforts focused on novel antidepressant therapies and increasing diagnosis of mental health conditions are expected to strengthen the segment's market leadership throughout the forecast period.
Increasing burden of central nervous system disorders is a key factor driving growth of the CNS disorders therapeutics market. There is a rising incidence of neurological and psychiatric conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, depression, and schizophrenia. For instance, around 50 million people globally are living with epilepsy, according to the Similarly, an estimated 13 million Americans aged 65 and older are expected to be living with Alzheimer’s disease by 2050. This expanding patient pool is anticipated to drive demand for CNS therapeutics during the forecast period.
Growing mental health awareness and improving diagnostic capabilities are increasing the identification and treatment rates of conditions such as depression, anxiety, bipolar disorder, and other psychiatric and neurodegenerative diseases. This is expected to create lucrative growth opportunities for central nervous system (CNS) disorders therapeutics market during the forecast period.
In parallel, improvements in digital health and brain care are helping doctors detect and manage CNS disorders earlier. For example, the Imperial College Healthcare NHS Trust has introduced a home monitoring service for dementia patients that uses remote tools and smart technology to track health changes as well as support early care. Such developments show how technology is becoming an important part of CNS care, improving patient outcomes and expanding treatment options.
Development of novel drugs and treatments for central nervous system disorders is a key market-shaping trend. The market is seeing increased adoption of biologics, immunotherapies, and advanced molecular therapies alongside traditional small-molecule drugs. In August 2025, for instance, Sumitomo Pharma sought an approval to manufacture and sell a drug that utilizes iPS cells to target advanced Parkinson’s disease in Japan. This was following the success of its trial in terms of proving safety and effectiveness of the regenerative stem cell treatment for the disease.
|
Current Event |
Description and its Impact |
|
WHO Highlights the Growing Burden of Neurological Disorders |
|
|
Expansion of FDA Approvals for CNS Therapies (2025–2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America is expected to hold 41% of the global central nervous system disorders therapeutics market share in 2026. This is attributable to rising burden of neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease, along with strong diagnosis rates for psychiatric conditions like depression, anxiety, and schizophrenia. Presence of advanced healthcare infrastructure and high adoption of novel CNS drug classes like antidepressants, anticonvulsants, and antipsychotics are also supporting market expansion in the region.
Increasing prevalence of neurodegenerative disorders, particularly Alzheimer’s disease, is playing a key role in boosting growth of North America central nervous system disorders therapeutics market. According to the Alzheimer’s Association, about 13 million Americans aged 65 and older are expected to live with Alzheimer’s disease by 2050. This expanding patient pool is set to fuel demand for neurodegenerative therapeutics.
Asia Pacific is anticipated to emerge as a highly lucrative market for central nervous system disorders therapeutics companies during the forecast period, registering a CAGR of 9.1%. This is mainly due to increasing prevalence of neurological and psychiatric disorders, rising urban stress-related conditions, and improving access to mental healthcare services. Growing adoption of antidepressants, antipsychotics, and anticonvulsants, along with increasing awareness of early diagnosis and treatment of CNS disorders, is also supporting market expansion in the region.
The growing burden of mental and neurological disorders is significantly increasing demand for CNS therapeutics and fostering market growth in Asia Pacific. According to the World Health Organization (WHO), an estimated 289 million people live with a mental, neurological, or substance use condition in the WHO South-East Asia Region. The large patient pool underscores the significant unmet need for CNS therapies, facilitating growth in the market across the region.
The United States is expected to remain a leading market for central nervous system disorders therapeutics during the forecast period. This is due to its advanced neuro-oncology and psychiatric care infrastructure, along with strong adoption of innovative drug classes such as antidepressants, anticonvulsants, and targeted biologics.
Rising adoption of precision medicine approaches, including immunotherapy and molecularly targeted therapies, coupled with the widespread use of advanced diagnostic tools such as MRI and genetic testing for earlier and more accurate diagnosis of CNS disorders, is also driving market growth in the country. Reflecting this trend, the U.S. Food and Drug Administration approved Ztalmy for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, highlighting continued innovation in therapies for rare neurological disorders.
The central nervous system disorders therapeutics market in China is projected to witness strong growth during the assessment period. This can be attributed to its large patient population and rapidly improving access to advanced neurological and oncology care. Expansion of healthcare infrastructure, increasing availability of neurosurgical procedures, and rising use of modern CNS drug classes such as antipsychotics, antidepressants, and anticonvulsants are supporting market expansion.
Some of the major players in central nervous system disorders therapeutics market are Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals.
Top manufacturers of central nervous system disorders therapeutics are adopting various organic and inorganic strategies to boost their sales as well as gain a competitive edge in the industry. These include new product launches and approvals, increasing investments in R&D, clinical trials, mergers, acquisitions, distribution agreements, partnerships, collaborations, and joint ventures.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 139,307 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.4% | 2033 Value Projection: | USD 228,639 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
